基于临床、放射学和病理特征，开发一种用于分层评估脑内孤立纤维瘤（ISFT）肿瘤复发（TR）的评分图。本研究纳入了来自XXX和XXX的215名和48名ISFT患者，其诊断基于组织病理学结果。将患者按随机比例8:2分为训练组和测试组。对临床、放射学和病理特征以及临床结果进行回顾性分析。使用Cox比例风险模型对训练组的TR进行单变量和多变量分析。在训练组中开发结合独立风险因素的评分图，并在测试组中进行验证。使用Harrell C指数分析其预测性能。决策曲线分析（DCA）用于评估净临床获益。测试组TR在3年和5年的Harrell C指数分别为0.845（0.578-0.944）和0.807（0.612-0.901）。在测试组中，评分图相较于TR方案或非TR方案在DCA中提供了净临床获益。尽管术后放射治疗（PORT）对TR预防有用，但高剂量（≥46 Gy）并不能优于低剂量延长无进展生存期。本研究获得的评分图具有良好的预测性能，可用于ISFT患者。版权所有©2023年The Association of University Radiologists。Elsevier Inc.保留所有权利。

To develop a nomogram to stratify tumor recurrence (TR) in intracranial solitary fibrous tumors (ISFTs) based on the clinical, radiological, and pathological features.A total of 215 patients from XXX and 48 patients from XXX, diagnosed with ISFT based on histopathological findings, were included. The patients were randomly divided into training and test cohorts at a ratio of 8:2. Information regarding clinical, radiological, and histopathological features, and the clinical outcomes was retrospectively analyzed. Univariate and multivariate analyses were performed using the Cox proportional hazard model for TR in the training cohort. A nomogram incorporating the independent risk factors was developed in the training cohort and validated in the test cohort. Its predictive performance was analyzed using the Harrell C-index. Decision curve analysis (DCA) was used to evaluate the net clinical benefit.The Harrell C-indices for TR at 3 and 5 years were 0.845 (0.578-0.944) and 0.807 (0.612-0.901) for the test cohort, respectively. In the test cohort, the nomogram provided a net clinical benefit in the DCA over the TR scheme or non-TR scheme. Although postoperative radiotherapy (PORT) was useful for TR prevention, high doses (≥46 Gy) were not superior to lower doses in prolonging the progression-free survival.The nomogram obtained in our study had a good predictive performance and could be used for ISFT patients.Copyright © 2023 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.